Zhejiang Dayang Biotech Group (003017.SZ) announced that on October 17, 2024, the company held the 20th meeting of the fifth board of directors, reviewing and approving the proposal on investing in the construction of an annual output of 800 tons of amprolium hydrochloride relocation and expansion project, agreeing that the company will invest 0.3019 billion yuan of self-raised funds in the construction of the project.
In order to further expand the scale of the company's advantageous product operation, enhance product market competitiveness, and respond to Jiande City's policies of "phasing out backward production capacities while introducing advanced ones" and industrial transformation, by relocating the production processes involving hazardous chemicals to the park, the company has decided to implement the amprolium hydrochloride relocation and expansion project. The purpose is to continuously strengthen safety and environmental protection management, properly resolve various risks. Through relocation, the company aims to enhance the safety level of its existing production area, strengthen the competitive advantages of new projects in energy conservation, emission reduction, automation, intelligence, clean production, comprehensive resource utilization, circular economy, and other green processes to adapt to the development of the times.
